Hydra Biosciences, Inc.

Hydra Biosciences, Inc.

Hydra Biosciences, Inc.

Date Founded



405 Concord Avenue,Suite 147,Belmont, MA 02478

Type of Company


Employees (Worldwide)

11 - 50


Medical Support Services
Holding Companies

Company Description

Hydra Biosciences, Inc. develops pharmaceutical products. It is focused in major therapeutic areas, which include pain, inflammation, renal, anxiety, and pulmonary diseases. The company was founded by Laurie Bartlett Keating, Dean Y. Li, David E. Clapham, and Mark T. Keating in 2001 and is headquartered in Belmont, MA.

Contact Data
Trying to get in touch with decision makers at Hydra Biosciences, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Senior Vice President, Chemistry, Pharmacology & Preclinical Development, Consultant

Director of Target Discovery

Director of Clinical Operations

Board of Directors

General Partner at Advanced Technology Ventures

Chief Executive Officer & Director at Adenium Biotech ApS

Paths to Hydra Biosciences, Inc.
Potential Connections via
Relationship Science
Hydra Biosciences, Inc.
Recent Transactions
Details Hidden

Hydra Biosciences, Inc. raised money in a private placement transaction

Advisors & Consultants
Legal Advisor

Partner at Wilmer Cutler Pickering Hale and Dorr LLP

Non-Profit Donations & Grants
$25K - $50K
$25K - $50K
Details Hidden

Advanced Technology Ventures' (ATV) investment strategy focuses on emerging growth technology businesses in information technology, healthcare and clean technology. The majority of their portfolio companies are based in North America with a few located in Europe and Israel. They target companies with exceptional management teams with solid operational experience and deeply rooted domain expertise. ATV's investment strategy is rooted in portfolio diversification, minimal reliance on stock- market performance, active monitoring of portfolio companies and disciplined management of existing investments. They typically originate and lead initial syndications of their investments. Once an investment has been syndicated, ATV remains actively involved in board membership and helps in a variety of functional, strategic and financial roles. In particular, they assist their portfolio companies in developing their management teams, refining their competitive strategies and strengthening industry alliances.

Details Hidden

Lilly Ventures Management Co. focuses on investments in the biotechnology, medical technology and healthcare information technology sectors. The firm manages four funds: the e.Lilly Venture Fund, the Lilly BioVenture Fund, the Lilly MedTech Venture Fund and the Lilly Asian Ventures Fund.The e.Lilly Venture Fund targets investments in early- to development-stage start-up companies with e-business solutions that focus on the research, development and commercialization of pharmaceuticals. Investments range up to $3 million.The Lilly BioVenture Fund invests in early-stage biotechnology companies with pioneering drug discovery and development technologies and novel therapies.The Lilly MedTech Venture Fund targets investments in companies that are developing emerging technologies in the medical technology sector. The fund targets companies with innovative diagnostic technologies and therapeutic devices and combination products incorporating pharmaceuticals, medical devices or diagnostics. Initial investments range up to $5 million.The Lilly Asian Ventures makes venture capital investments in life science companies with strong management teams and innovative technology and/or business models. The fund targets companies at various stages of development from start-up to commercialization. Specific areas of interest include biotechnology and pharmaceuticals, medical devices and diagnostics and healthcare services. Their focus is mainly on opportunities in China but they will consider investment opportunities elsewhere in east and south Asia.

Details Hidden

Abingworth is an active, long-term manager which invests exclusively in companies in the life sciences and healthcare sectors including biotherapeutics, small molecules, nucleic acid therapeutics, vaccines, specialty pharma, technologies, medical devices, diagnostics, instrumentation. Their geographic focus is primarily on the US, UK and Europe.The firm seeks to invest USD 15-30 million in small-cap early and late-stage venture, growth equity and public biotechnology companies with strong management and novel technology that offers a significant improvement over current approaches.Abingworth takes minority or majority stakes in their investee companies, seeking to build relationships with management to create world-class companies.They typically hold an investment for three to eight years.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Hydra Biosciences, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Hydra Biosciences, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Hydra Biosciences, Inc..